Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia

This Phase 2 study will investigate the antitumor activity in terms of ORR of tipifarnib in
approximately 20 eligible subjects with CMML. This trial is planned as a single treatment
trial with statistical comparison to historical ORR rate. The primary objective is to provide
evidence that the TRUE underlying ORR in all subjects and/or in the KRAS/NRAS wild-type
subgroup exceeds the historical rate. Only consented subjects who meet all eligibility
criteria will be enrolled in the study. Eligible subjects will receive tipifarnib
administered at a starting dose of 1200 mg or 900 mg, orally with food, bid for 7 days in
alternating weeks (Days 1-7 and 15-21) in 28 day cycles. Stepwise 300 mg dose reductions to
control treatment-related, treatment-emergent toxicities are allowed.

If a complete response is observed, therapy with tipifarnib will be maintained for at least 6
months beyond the start of response. In the absence of unmanageable toxicities, subjects may
continue to receive tipifarnib treatment until disease progression. Provisions will be made
for the continuation of study treatment in subjects whose disease has not progressed beyond
the end of the study, e.g. a single patient treatment protocol.

Determination of disease response will be performed by the Investigator according to the
MDS/MPN IWG criteria. Similarly, disease progression will also be determined based on the
MDS/MPN IWG criteria. Upon disease progression, all subjects will be followed approximately
every 12 weeks for survival and the use of subsequent therapy until either death or 12 months
after accrual of the study cohort has been completed, whichever occurs first. Information on
survival and subsequent anticancer therapy may be collected by phone.

Inclusion Criteria:

- Diagnosis of CMML as defined by the World Health Organization (WHO) criteria.

- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.

- Subject is willing and able to comply with scheduled visits, treatment plans,
laboratory tests and other procedures (including bone marrow assessments).

- At least 1 week since the last systemic therapy regimen prior to Cycle 1 Day 1.
Subjects on a stable dose of hydroxyurea for at least 2 weeks prior to Cycle 1 Day 1
may continue on hydroxyurea until Cycle 1 Day 7. Subjects must have recovered to NCI
CTCAE v. 4.03 < Grade 2 from all acute toxicities (excluding Grade 2 toxicities that
are not considered a safety risk by the Sponsor and Investigator) or toxicity must be
deemed irreversible by the Investigator.

- Acceptable liver function:

1. Total or direct bilirubin ≤ 2 times upper limit of normal (x ULN); does not apply
to subjects with Gilbert's syndrome diagnosed as per institutional guidelines.

2. AST (SGOT) and ALT (SGPT) ≤ 2.5 x ULN.

- Acceptable renal function with serum creatinine ≤ 1.5 x ULN or a calculated creatinine
clearance ≥ 60 mL/min using the Cockcroft-Gault or Modification of Diet in Renal
Disease formulas.

- Female subjects must be:

1. Of non-child-bearing potential (surgically sterilized or at least 2 years
post-menopausal); or

2. If of child-bearing pIf of child-bearing potential, subject must use an adequate
method of contraception consisting of two-barrier method or one barrier method
with a spermicide or intrauterine device. Both females and male subjects with
female partners of child-bearing potential must agree to use an adequate method
of contraception for 2 weeks prior to screening, during, and at least 4 weeks
after last dose of study medication. Female subjects must have a negative serum
or urine pregnancy test within 72 hours prior to start of study medication.

3. Not breast feeding at any time during the study.

- Written and voluntary informed consent understood, signed and dated.

Exclusion Criteria:

- Known prior progression to acute myeloid leukemia (AML) defined by at least 20% blasts
in the blood or bone marrow.

- Myeloproliferative/myelodysplastic syndrome other than CMML. CMML with t(5;12) that
have not yet received imatinib.

- Participation in any interventional study within 4 weeks of randomization or 5
half-lives of the prior treatment agent (whichever is longer).

- Ongoing treatment with an anticancer agent for CMML not contemplated in this protocol.
Subjects on a stable dose of hydroxyurea for at least 2 weeks prior to Cycle 1 Day 1
may continue on hydroxyurea until Cycle 1 Day 7.

- Concurrent use of granulocyte macrophage colony-stimulating factor (GM-CSF).

- Prior treatment (at least 1 full treatment cycle) with a farnesyltransferase
inhibitor.

- Active coronary artery disease requiring treatment, myocardial infarction within the
prior year, New York Heart Association grade III or greater congestive heart failure,
cerebro-vascular attack within the prior year, or current serious cardiac arrhythmia
requiring medication except atrial fibrillation.

- Major surgery, other than diagnostic surgery, within 2 weeks prior to Cycle 1 Day 1,
without complete recovery.

- Active, concurrent malignancy requiring radiation, chemotherapy, or immunotherapy
(excluding non-melanoma skin cancer, adjuvant hormonal therapy for breast cancer and
hormonal treatment for castration sensitive prostate cancer).

- Active and uncontrolled bacterial, viral, or fungal infections, requiring systemic
therapy. Known infection with human immunodeficiency virus (HIV), or an active
infection with hepatitis B or hepatitis C.

- Concomitant disease or condition that could interfere with the conduct of the study,
or that would, in the opinion of the investigator, pose an unacceptable risk to the
subject in this study.

- The subject has legal incapacity or limited legal capacity.

- Significantly altered mental status that would limit the understanding or rendering of
informed consent and compliance with the requirements of this protocol. Unwillingness
or inability to comply with the study protocol for any reason.